Buy BPC-157 Peptide: $2.45/mg in the US, $2.94/mg in the UK

BPC-157 is a synthetic pentadecapeptide: fifteen amino acids in a fixed order, formula C62H98N16O22, around 1,419.5 g/mol. The sequence is a partial fragment of a protein found in gastric juice, which is where the name comes from, and it is made by solid-phase synthesis rather than extracted from anything.

What ships is that peptide freeze-dried into a small white cake or film at the bottom of a vial, usually as an acetate salt, sealed under a crimped stopper. There is no excipient system, no buffer, no preservative and no diluent in the box. A 10 mg vial holds 10,000 mcg of labelled mass and nothing else.

What the vial is not is a medicine. A formulated drug arrives with a strength, an indication, a route and a marketing authorisation behind it. This arrives with a compound name, a mass and a batch code, and the labelling says research use only because that is what it is. If a listing describes a BPC-157 vial in the language of a prescription product, the listing is wrong about its own product. Our primer on peptides covers where compounds like this sit relative to approved peptide drugs.

The second BPC-157 listing, the Wolverine Stack, is the same idea with two compounds in one vial: 10 mg of BPC-157 and 10 mg of TB-500, a synthetic fragment of thymosin beta-4. Its headline $2.25 per milligram covers both, so it is not a cheaper way to buy BPC-157 on its own.

Price per milligram assumes the milligram is peptide. Some of it is not, and the gap is a certificate question rather than a pricing question.

Lyophilised peptides are weighed as a salt. The mass in the vial includes counterions from synthesis and purification, residual water and residual solvent, so net peptide content is always some percentage below the labelled mass. That figure is measured separately from chromatographic purity, and the two are routinely confused. Purity by HPLC says what fraction of the peptide present is the right peptide. Peptide content says what fraction of the powder is peptide at all. A vial can be 99% pure and still be well under 100% peptide by mass.

Neither number can be inferred from a price, and neither should be taken from a generic page on a vendor site. It has to come from the certificate covering the batch printed on your vial. Ascension publishes two third-party assays per batch, from Kovera Labs (batch #12-05260628) and MZ Biolabs (batch #12-01260229), and the useful check is simply that the batch on the paperwork matches the batch on the label in your hand.

Identity matters as much as quantity. Mass spectrometry confirms the molecule weighs what a 15-residue BPC-157 should weigh; chromatography confirms how much of the sample is that molecule. A certificate with one and not the other has answered half the question.

The vial has no concentration until it is reconstituted, which means the buyer sets the arithmetic. This is laboratory handling, not a protocol.

Every row describes the same 10,000 mcg and the same $24.50. Doubling the volume halves the mass in each unit and halves the cost per unit, from $0.245 at 10 mg/mL to $0.1225 at 5 mg/mL, while the cost per 100 mcg stays at $0.245 throughout. Volume buys measurement resolution, not economy, and anyone quoting a cost per unit without stating the mg/mL is quoting a number that means nothing.

The mechanics are covered in our reconstitution guide, the barrel markings in the syringe measurement guide, and the calculator will run any volume you enter. Dry vials are stable at refrigerator temperature; once in solution the clock starts, which the storage guide covers.

There is no UK route that makes this a normal purchase. BPC-157 holds no MHRA authorisation and no EMA authorisation, so no UK pharmacy can supply it and no prescriber can write for it. What exists is a US research listing and an international parcel.

Two mechanisms decide who collects the VAT. On consignments valued at £135 or less, UK VAT is due at the point of sale and an overseas seller is expected to charge it. Above that threshold it is collected at the border, usually with a carrier handling charge added before the parcel is released, as the government guidance on goods sent from abroad sets out. One $24.50 vial sits well below the line; a ten-vial order at $245.00 may not, depending on the rate on the day.

The tax is the smaller half. An unapproved medicinal product entering the UK can be examined, detained or refused, and that outcome falls on the buyer, not the seller. We do not offer suggestions for reducing customs scrutiny and would not, because the exposure is real and the mitigation is a decision about whether to order at all. EU buyers face the same structure with national VAT rates and their own customs practice in place of the UK numbers.

Search for a domestic supplier and you will find sites with British spelling, GBP prices and a UK contact address. Very few of them hold stock in the UK, because holding stock of an unapproved medicinal product in the UK is the part that carries the exposure.

The usual arrangement is that the order is passed to a US or Chinese supplier and shipped from there, with the UK site taking a margin for the introduction. What the buyer gets is the same parcel crossing the same border, plus a markup, minus the ability to check the original batch certificate. Three questions settle it before you pay: where does the parcel physically ship from, what batch code will be on the vial, and which laboratory issued the certificate for that batch. A supplier that cannot answer the second and third is not a stockist in any useful sense.

Convert whatever you are quoted into landed cost per milligram and compare it with $2.94, which is the US listing with 20% VAT applied and nothing else. Anything materially above that is paying for the introduction. Anything materially below it is worth a second look at the certificate rather than at the price. The sibling guides on where to buy BPC-157 and choosing a source work through the supplier criteria in detail, and the retatrutide UK page applies the same import arithmetic to a different compound.

The United States position moved twice in 2026, and most pages are still quoting the old one. BPC-157 has never been approved for any indication and has no USP or NF monograph. It was placed in FDA's Category 2 for nominated bulk substances in September 2023. In April 2026 FDA removed it from Category 2 after the nominations were withdrawn, which is a removal for further evaluation and not a promotion to Category 1. At the Pharmacy Compounding Advisory Committee meeting of 23 and 24 July 2026 the committee narrowly recommended BPC-157 for the 503A Bulks List, and that recommendation is non-binding: the substance does not appear in 21 CFR 216.23 and FDA has issued no final determination. Unapproved, out of Category 2, recommended but not listed.

The UK and EU position has not moved at all. No authorisation, no compounding pathway, no lawful supply route. Buying research material in the US is legal when it is sold and bought as research material; importing it privately is where the risk starts.

Two more things a buyer should know. WADA prohibits BPC-157 at all times under S0, the non-approved substances class, which covers any compound without current human therapeutic approval, so it is relevant to anyone in a tested sport. And the evidence is thinner than its reputation: the tendon, ligament and gut findings are almost entirely rat and cell work, much of it from a single research group in Zagreb. No human efficacy trial has reported yet. The first controlled test began on 2 February 2026: NCT07437547, a Phase 2 study in acute hamstring strain sponsored by Hudson Biotech, with 120 participants and primary completion not before 14 February 2027.